The Introduction of Halothane into Clinical Practice: The Oxford Experience

Abstract

This paper reviews the clinical situation in anaesthesia before the introduction of halothane into clinical practice in 1956, emphasising the limitations of agents available at the time. The background to the development of halogenated hydrocarbon compounds as anaesthesia agents is presented, including the involvement of Imperial Chemical Industries in England. The Nuffield Department of Anaesthetics was involved in the clinical trials and the designing and execution of these. The results of their work and the problems encountered are presented.

Keywords

anaesthesia halothane history Oxford Nuffield Department

References

Furness

D.N.

Controlled respiration in neurosurgery.

Br J Anaesth 1957; 29: 415.

Suckling

C.W.

Some chemical and physical features in the development of Fluothane.

Br J Anaesth 1957; 29: 446–470.

Raventos

“The action of Fluothane, a new volatile anaesthetic”.

Br J Pharmacol 1956; 11: 83.

Bull

“The Start of the halothane story”.

Today's anaesthetist 1997; 12, 3.

Epstein

H.G.

Macintosh RR. An anaesthetic inhaler with automatic thermo-compensation.

Anaesthesia, 1956; 11: 83.

Bryce-Smith

, O'Brien

H.D.

Fluothane; a non-explosive volatile anaesthetic agent.

BMJ 1956; 2: 969.

Bryce-Smith

, O'Brien

H.D.

Some observations on Fluothane.

Proc Roy Soc Med 1956; 50: 15.

O'Brien

H.D.

Fluothane.

Aust NZ J Surg 1958; 28: 110–119.

Jones

R.M.

Desflurane and sevoflurane: inhalational anaesthetics for this decade?

Br J Anaesth 1990; 65: 527.